Drug intelligence / Profile preview

JT109

Development stage: Preclinical
Lead developer: Junshi Biosciences

Overview

JT109 is an investigational therapeutic candidate being developed by Junshi Biosciences in collaboration with Coherus BioSciences, specifically targeting infectious diseases. While detailed information regarding its specific molecular target and modality remains limited in public disclosures, it is part of a broader portfolio of anti-infective agents developed by Junshi, which includes treatments for COVID-19 such as the oral antiviral mindeudesivir (VV116) and the monoclonal antibody etesevimab (JS016). JT109 is currently in the early stages of development, and its precise mechanism of action has not been widely publicized.

Beyond the preview

Go deeper on JT109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JT109.

Explore the full profile